Wealthfront Advisers LLC Buys Shares of 249,605 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Wealthfront Advisers LLC purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 249,605 shares of the company's stock, valued at approximately $9,268,000. Wealthfront Advisers LLC owned 0.52% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares during the period. Parkside Financial Bank & Trust raised its position in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after buying an additional 871 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after acquiring an additional 398 shares during the period. KBC Group NV boosted its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after acquiring an additional 650 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Amphastar Pharmaceuticals by 90.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company's stock worth $156,000 after acquiring an additional 1,992 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Amphastar Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ AMPH traded down $0.04 during trading on Thursday, reaching $26.24. 467,567 shares of the stock were exchanged, compared to its average volume of 586,316. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of 8.75, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The business's 50-day moving average price is $33.13 and its 200 day moving average price is $41.55. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a twelve month low of $25.89 and a twelve month high of $53.96.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 27.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently commented on AMPH. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective for the company. Piper Sandler cut Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.